AGREEMENT AND PLAN OF MERGER BY AND AMONG ASTELLAS PHARMA INC., ASTELLAS US HOLDING, INC., RUBY ACQUISITION, INC., AND OSI PHARMACEUTICALS, INC. DATED AS OF MAY 16, 2010Agreement and Plan of Merger • May 17th, 2010 • Astellas Pharma Inc. • In vitro & in vivo diagnostic substances • Delaware
AGREEMENT AND PLAN OF MERGER, dated as of May 16, 2010 (this “Agreement”), by and among Astellas Pharma Inc., a corporation formed under the laws of Japan (“Parent”), Astellas US Holding, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent, Ruby Acquisition, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Holding and an indirect wholly-owned subsidiary of Parent (“Merger Sub”), and OSI Pharmaceuticals, Inc. a Delaware corporation (the “Company”).
AUDENTES THERAPEUTICS, INC.Merger Agreement • December 16th, 2019 • Astellas Pharma Inc. • Biological products, (no disgnostic substances)
The information contained in this Summary Term Sheet is a summary only and is not meant to be a substitute for the more detailed description and information contained in the remainder of this Offer to Purchase (as it may be amended, supplemented or otherwise modified from time to time, the “Offer to Purchase”), the Letter of Transmittal (as it may be amended, supplemented or otherwise modified from time to time, the “Letter of Transmittal”) and other related materials. You are urged to read carefully this Offer to Purchase, the Letter of Transmittal and other related materials in their entirety. This Summary Term Sheet includes cross-references to other sections of this Offer to Purchase where you will find more complete descriptions of the topics mentioned below. The information concerning Audentes contained in this Summary Term Sheet and elsewhere in this Offer to Purchase has been provided to Astellas and Purchaser by Audentes or has been taken from, or is based upon, publicly avail
